Jazz Pharmaceuticals (JAZZ) Is Up 5.1% After Monetizing FDA Voucher And Expanding Oncology Collaboration [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
antibody zanidatamab in HER2-positive breast cancer within Boehringer's ongoing Beamion-BCGC1 trial. Around the same time, Jazz also sold a US$200,000,000 FDA priority review voucher earned from Modeyso's approval, highlighting how its rare-disease work is translating into tangible financial resources for future development. We'll now explore how monetizing the US$200,000,000 priority review voucher may influence Jazz Pharmaceuticals' investment narrative and future growth profile. These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs . Discover why before your portfolio feels the trade war pinch. To own Jazz Pharmaceuticals, you need to believe it can replace aging sleep revenues with a focused oncology and neuroscience portfolio, led by assets like zanidatamab and Modeyso. The Boehringer Ingelheim collaboration and the US$200,000,000 voucher sale both support that oncology story, but they do not change the near term rea
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals price target raised to $235 from $210 at Needham [Yahoo! Finance]Yahoo! Finance
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Truist Financial Corporation from $220.00 to $230.00. They now have a "buy" rating on the stock.MarketBeat
- Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target raised by analysts at Needham & Company LLC from $210.00 to $235.00. They now have a "buy" rating on the stock.MarketBeat
- Is Jazz Pharmaceuticals (JAZZ) Offering Value After Recent Pullback And 32.7% One Year Gain [Yahoo! Finance]Yahoo! Finance
- Assessing Jazz Pharmaceuticals (JAZZ) Valuation After Recent Share Price Weakness [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 11/5/25 - Beat
JAZZ
Sec Filings
- 1/12/26 - Form 8-K
- 1/8/26 - Form 4
- 12/11/25 - Form 4
- JAZZ's page on the SEC website